Your session is about to expire
← Back to Search
Insulin
Faster Insulin Aspart (Fiasp®) for Type 1 Diabetes (PLATEAU Trial)
Phase 4
Waitlist Available
Research Sponsored by Mountain Diabetes and Endocrine Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male and female patients > 18 years of age
Type 1 DM of > 1 year duration
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 25 weeks
Awards & highlights
PLATEAU Trial Summary
This trial is comparing the efficacy of two types of insulin in terms of time to recovery from hyperglycemia.
Eligible Conditions
- Type 1 Diabetes
PLATEAU Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPLATEAU Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 25 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~25 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Time to stabilization of rising blood sugar by CGM after correction bolus
Secondary outcome measures
Change in Insulin On Board
Change in Insulin Sensitivity Factor
GlycoMark differences between arms
+5 morePLATEAU Trial Design
2Treatment groups
Active Control
Group I: Faster Insulin Aspart (Fiasp®)Active Control1 Intervention
In the Fiasp group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Fiasp is put into their pump and delivered to their body through a small tube placed under their skin. In this Fiasp treatment group, the subject will take fiasp with each meal while their pump also gives them a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
Group II: No Intervention: Conventional Insulin Aspart (NovoLog®)Active Control1 Intervention
In the aspart group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Aspart is put into their pump and delivered to their body through a small tube placed under your skin. In this NovoLog®-only treatment group, the subject will take aspart with each meal while your pump also gives you a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
Find a Location
Who is running the clinical trial?
Mountain Diabetes and Endocrine CenterLead Sponsor
3 Previous Clinical Trials
117 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger